NRx Pharmaceuticals (NASDAQ:NRXP) Announces Quarterly Earnings Results, Misses Estimates By $0.10 EPS

NRx Pharmaceuticals (NASDAQ:NRXPGet Free Report) announced its quarterly earnings results on Friday. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.10), Zacks reports.

NRx Pharmaceuticals Stock Up 13.5 %

Shares of NRXP opened at $2.35 on Friday. NRx Pharmaceuticals has a twelve month low of $1.10 and a twelve month high of $6.01. The company has a 50 day moving average of $3.02 and a 200-day moving average of $2.02. The stock has a market capitalization of $39.75 million, a P/E ratio of -1.10 and a beta of 1.22.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $19.00 price objective on shares of NRx Pharmaceuticals in a research report on Friday. D. Boral Capital reissued a “buy” rating and set a $31.00 price objective on shares of NRx Pharmaceuticals in a research report on Tuesday, January 28th. Finally, Ascendiant Capital Markets boosted their price objective on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, December 2nd.

View Our Latest Stock Report on NRx Pharmaceuticals

Insider Activity at NRx Pharmaceuticals

In other news, Chairman Jonathan C. Javitt acquired 40,000 shares of the firm’s stock in a transaction dated Tuesday, December 17th. The stock was bought at an average price of $1.17 per share, with a total value of $46,800.00. Following the transaction, the chairman now directly owns 84,634 shares in the company, valued at approximately $99,021.78. The trade was a 89.62 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 19.00% of the stock is owned by insiders.

NRx Pharmaceuticals Company Profile

(Get Free Report)

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.

Further Reading

Earnings History for NRx Pharmaceuticals (NASDAQ:NRXP)

Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.